포트리스 바이오텍(FBIO)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.51 (+0.00%), 시가총액 $0.08B, 52주 최저~최고 $1.70 ~ $4.38.
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the th
포트리스 바이오텍의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
포트리스 바이오텍의 현재 주가는 $2.51 (+0.00%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
포트리스 바이오텍의 시가총액은 약 $0.08B입니다.
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extende